SLC5A2 and heart failure: Conversely, data from the Swedish Heart Failure Registry (November 2020 to August 2022) indicated an increase in SGLT2 inhibitor use from 20.5% to 59.0% over time; ARNI prescriptions also rose, with a Japanese study showing a 43.9% rate between July 2021 and September 2022.